Using a unique and innovative theranostics approach, Spectral Diagnostics is committed to decreasing the unacceptably high mortality rates caused by sepsis. By combining complementary diagnostics and therapeutics, or theranostics, Spectral’s vision is to provide products that will enable vastly improved outcomes of patients with severe sepsis. Spectral is currently conducting a Phase III clinical trial for its lead product, Toraymyxin, for the treatment of patients with septic shock. Toraymyxin is a therapeutic hemoperfusion device that removes circulating endotoxin from the bloodstream, which may result in a significant reduction in mortality.